IGFBP2: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tags: mobile edit mobile web edit
 
CSV import
 
(One intermediate revision by the same user not shown)
Line 26: Line 26:
{{Protein-stub}}
{{Protein-stub}}
{{Medicine-stub}}
{{Medicine-stub}}
{{No image}}
__NOINDEX__

Latest revision as of 14:27, 17 March 2025

IGFBP2 or Insulin-like growth factor-binding protein 2 is a protein that in humans is encoded by the IGFBP2 gene. It is one of six high-affinity IGF binding proteins (IGFBP1 - IGFBP6) in the IGFBP family.

Function[edit]

IGFBP2 is a secreted protein that binds both IGF-I and IGF-II with high affinity. The binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. IGFBP2 has been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture depending on the cell type. It has been shown to be overexpressed in several cancers, including ovarian, breast, and prostate cancer.

Clinical significance[edit]

Studies have shown that high levels of IGFBP2 are associated with poor prognosis in several types of cancer, including glioblastoma, ovarian cancer, and prostate cancer. It is thought that IGFBP2 may promote cancer progression by enhancing cell survival, migration, and invasion. In addition, IGFBP2 has been implicated in insulin resistance, a condition that can lead to type 2 diabetes and metabolic syndrome.

Research[edit]

Research into IGFBP2 has focused on its role in cancer progression and its potential as a therapeutic target. Several studies have investigated the use of IGFBP2 inhibitors as a potential treatment for cancer. In addition, research is ongoing to better understand the role of IGFBP2 in insulin resistance and metabolic syndrome.

See also[edit]

References[edit]

<references />

Stub icon
   This article is a protein-related stub. You can help WikiMD by expanding it!




Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!